Ravulizumab
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Ravulizumab and local guidelines before prescribing.
Complement inhibitor
Mechanism
Long-acting complement C5 inhibitor.
Uses
Paroxysmal nocturnal haemoglobinuria, atypical HUS, myasthenia gravis.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Meningococcal infection, headache, infusion reactions.
Interactions
Few.
Contraindications and cautions
Unresolved meningococcal infection
Monitoring
Infection signs
Pregnancy and breastfeeding
Avoid unless essential
Renal and hepatic impairment
No adjustment
Overdose and reversal
Supportive
Special advice
Meningococcal vaccination and antibiotic prophylaxis; alert card.
More from the textbook: uses, cautions and other points
- Complement inhibitors - eculizumab and ravulizumab (C5), pegcetacoplan (C3), iptacopan (factor B) - PNH and atypical HUS; meningococcal vaccination (and often antibiotic prophylaxis) is essential - high risk of meningococcal infection.
Haematology: Anatomy Physiology and Pharmacology - Complement inhibitors (eculizumab, ravulizumab) | Meningococcal infection - vaccination (ACWY and B) and often antibiotic prophylaxis essential
ID: Hospital infection, the immunocompromised host, vaccination and public health - Newer targeted drugs (specialist) - complement inhibitors (eculizumab, ravulizumab, zilucoplan - meningococcal vaccination needed) and FcRn blockers (efgartigimod, rozanolixizumab).
Neurology: Anatomy, Physiology and Pharmacology - Newer targeted drugs: inebilizumab (anti-CD19), satralizumab (anti-IL-6 receptor), eculizumab and ravulizumab (complement inhibitors - need meningococcal vaccination).
Neurology: Multiple Sclerosis and inflammatory disease - Refractory disease: Rituximab (especially MuSK); newer treatments - complement inhibitors (eculizumab, ravulizumab, zilucoplan - meningococcal vaccination needed) and FcRn blockers (efgartigimod, rozanolixizumab). Access through specialist centres varies.
Neurology: Neuromuscular disease - Complement inhibitors - eculizumab or ravulizumab (with meningococcal vaccination and antibiotic cover).
Haematology: Emergencies - Eculizumab / ravulizumab | Atypical HUS, PNH; meningococcal vaccination and antibiotic cover.
Haematology: Emergencies - Complement inhibitors - eculizumab , ravulizumab (C5), and newer agents (iptacopan, pegcetacoplan).
Haematology: Anaemia
Where it is discussed in the book
- Neurology: Anatomy, Physiology and Pharmacology (1 mention)
- Neurology: Multiple Sclerosis and inflammatory disease (1 mention)
- Neurology: Neuromuscular disease (1 mention)
- Haematology: Anatomy Physiology and Pharmacology (1 mention)
- Haematology: Emergencies (2 mentions)
- Haematology: Anaemia (2 mentions)
- ID: Hospital infection, the immunocompromised host, vaccination and public health (1 mention)
- Clinical Immunology: Immune system basics and immunological investigations (1 mention)
- Clinical Immunology: Primary immunodeficiency (1 mention)
- Clinical Immunology: Secondary immunodeficiency, the immunocompromised host and vaccination (1 mention)
- Clinical Immunology: Autoimmunity, autoantibodies and complement (3 mentions)
- Clinical Immunology: Biologics, immunotherapy, checkpoint toxicity and transplant immunology (1 mention)